What is Relmada Therapeutics, Inc.'s stock-based comp?

Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $288.54K in Q4 2025.

What does stock-based comp mean?

This represents the portion of share-based compensation expenses that are not tax-deductible under current tax regulations. It highlights the impact of equity-based incentive plans on the company's taxable income calculation.

Relmada Therapeutics, Inc. RLMD Stock-Based Comp

Stock-Based Comp at other companies

Target HospitalityTH

$480.25K+171%

USANA Health SciencesUSNA

$343.75K—

Proto LabsPRLB

$76K—

Dine Brands GlobalDIN

$325K—

ePlusPLUS

$608.5K+20.5%

Trex CompanyTREX

$25K+113%

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s stock-based comp?: Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $288.54K in Q4 2025.
What does stock-based comp mean?: This represents the portion of share-based compensation expenses that are not tax-deductible under current tax regulations. It highlights the impact of equity-based incentive plans on the company's taxable income calculation.